Galasko, Douglas

NPTX2 and cognitive dysfunction in Alzheimer’s Disease

Xiao, M.-F., Xu, D., Craig, M. T., Pelkey, K. A., Chien, C.-C., Shi, Y., Zhang, J., Resnick, S., Pletnikova, O., Salmon, D., et al. (2017) · eLife

Neuroscience and Neuropharmacology ResearchAlzheimer's disease research and treatments

Cited by 316

Clinical and neuropsychological differences between patients with earlier and later onset of Alzheimer's disease: A CERAD analysis, part XII

Koss, E., Edland, S., Fillenbaum, G., Mohs, R., Clark, C., Galasko, D., & Morris, J. C. (1996) · Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 150

Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group

Su, Y., Blazey, T. M., Owen, C. J., Christensen, J. J., Friedrichsen, K., Joseph-Mathurin, N., Wang, Q., Hornbeck, R. C., Ances, B. M., Snyder, A. Z., et al. (2016) · PLOS ONE

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 56

No Long-Term Effect of Behavioral Treatment on Psychotropic Drug Use for Agitation in Alzheimer's Disease Patients

Weiner, M. F., Tractenberg, R. E., Sano, M., Logsdon, R., Teri, L., Galasko, D., Gamst, A., Thomas, R., & Thal, L. J. (2002) · Journal of Geriatric Psychiatry and Neurology

Dementia and Cognitive Impairment ResearchPharmaceutical Practices and Patient Outcomes

Cited by 22